Saiama Waqar

Medicine & Life Sciences

1. Non-Small Cell Lung Carcinoma 100%
2. Small Cell Lung Carcinoma 44%
3. Lung Neoplasms 41%
4. Neoplasms 29%
5. Survival 24%
6. Drug Therapy 22%
7. Circulating Tumor DNA 21%
8. Radiotherapy 20%
9. durvalumab 19%
10. temsirolimus 17%
11. Platinum 17%
12. Therapeutics 16%
13. Squamous Cell Neoplasms 15%
14. Anaplastic Lymphoma Kinase 12%
15. atezolizumab 12%
16. Adjuvant Chemotherapy 12%
17. Thorax 11%
18. rovalpituzumab tesirine 10%
19. ensartinib 10%
20. Neoplasm Metastasis 10%
21. Etoposide 10%
22. Pemetrexed 10%
23. Confidence Intervals 9%
24. Mutation 9%
25. Medical Oncology 9%
26. Adenocarcinoma of Lung 9%
27. Maximum Tolerated Dose 8%
28. Carboplatin 8%
29. MP470 8%
30. Immunoconjugates 8%
31. Immunotherapy 7%
32. veliparib 7%
33. RRx-001 7%
34. TOR Serine-Threonine Kinases 7%
35. Safety 7%
36. Progression-Free Survival 7%
37. Human Influenza 7%
38. MLN 8237 6%
39. Neuroendocrine Tumors 6%
40. Epidemiology 6%
41. 130-nm albumin-bound paclitaxel 6%
42. ErbB Receptors 6%
43. Databases 6%
44. Nausea 6%
45. ramucirumab 6%
46. Vaccination 6%
47. palbociclib 6%
48. carfilzomib 6%
49. INCB018424 5%